Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced that data from Phase I and Phase II elagolix trials and preclinical work was ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE